reaction products of oxidation of 2-aminoanthracene-9,10-dione and chlorine

Acute Toxicity: oral

Administrative data

Endpoint:

acute toxicity: oral

Type of information:

other: read-across from supporting substance (structural analogue or surrogate)

Adequacy of study:

key study

Study period:

1976

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

comparable to guideline study with acceptable restrictions

Remarks:

The test was conducted by means of Read Across approach. Further information was attached at section 13

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1976

Report date:

1976

Materials and methods

Test guideline

Qualifier:

equivalent or similar to guideline

Guideline:

OECD Guideline 401 (Acute Oral Toxicity)

GLP compliance:

no

Test type:

standard acute method

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

Vat Blue 014 - Similar Substance 01

IUPAC Name:

Vat Blue 014 - Similar Substance 01

Test material form:

solid: particulate/powder

Test animals

Species:

rat

Strain:

other: Tif:RAIf

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: Ciba-Geigy
- Females (if applicable) nulliparous and non-pregnant: [yes]
- Weight at study initiation: 105 to 120 g
- Fasting period before study: overnight
- Housing: 5/cage
- Diet ad libitum: No 890 Nafag Gossau SG
- Water (e.g. ad libitum): tap
- Acclimation period: at least 5 days

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 +/- 1
- Humidity (%): 55 +/- 5
- Photoperiod (hrs dark / hrs light): 10/14

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

CMC (carboxymethyl cellulose)

Remarks:

2%

Details on oral exposure:

VEHICLE
- Concentration in vehicle: 10% (1000 mg/kg), 30% (3000 mg/kg), 25% (10000 and 15000 mg/kg)
- Amount of vehicle (if gavage): 10 ml/kg (1000 and 3000 mg/kg), 40 ml/kg (10000 mg/kg), 60 ml/kg (15000 mg/kg)

Doses:

1000, 3000, 10000, 15000 mg/kg bw

No. of animals per sex per dose:

5

Control animals:

no

Details on study design:

- Duration of observation period following administration: 15 days
- Frequency of weighing: Days 1 and 15
- Clinical signs and mortality: throughout observation period

Results and discussion

Effect levels

Effect levels 1

Key result

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 15 000 mg/kg bw

Based on:

test mat.

Effect levels 2

Sex:

male/female

Dose descriptor:

LD0

Effect level:

>= 15 000 mg/kg bw

Based on:

test mat.

Mortality:

none

Clinical signs:

1000 mg/kg bw: none
3000 mg/kg bw: reduction in spontaneous motility, ataxia, muscular hypotonia with partial hypertonia, hyperreflexia. After 3 days no symptoms
10000 mg/kg bw: reduction in spontaneous motility, ataxia, muscular hypotonia with partial hypertonia, hyperreflexia, hypoventilation, ventricumbency. After 3 days no symptoms
15000 mg/kg bw:reduction in spontaneous motility, ataxia, muscular hypotonia with partial hypertonia, hyperreflexia, hypoventilation, ventricumbency, diarrhea, humpbacked. After 3 days no symptoms

Body weight:

no abnormalities

Applicant's summary and conclusion

Interpretation of results:

other: CLP criteria not met

Conclusions:

LD50 > 15000 mg/kg bw

Executive summary:

The test substance did not cause any mortality up to 15000 mg/kg bw. The LD0 and LD50 is higher then 15000 mg/kg bw.